Patients with low CDKN2A and GLS expression, as well as those with high DLD, FDX1, DLAT, LIAS, PDHA1, and PDHB expression, exhibited an improved overall survival (OS), suggesting that the CRGs may impact the prognosis of COAD patients. This evidence concerns the gene CDKN2A and colon adenocarcinoma.